Amanote Research
Register
Sign In
OA12 a Phase I Study of Novel BCL-2/BCL-xL Inhibitor APG-1252 in Patients With Advanced SCLC or Other Solid Tumor
Journal of Thoracic Oncology
- United States
doi 10.1016/j.jtho.2018.10.022
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Oncology
Respiratory Medicine
Pulmonary
Date
December 1, 2018
Authors
Y. Wu
N.J. Lakhani
M. Boyer
Q. Zhou
D.W. Rasco
Y. Huang
L. Men
Y. Li
Z. Xia
H. Wang
J. Ji
B. Lu
Z. He
Q. Dong
D. Yang
Y. Zhai
Publisher
Elsevier BV
Related search
A Phase I Study of Obatoclax Mesylate, a BCL-2 Antagonist, Plus Topotecan in Solid Tumor Malignancies
Cancer Chemotherapy and Pharmacology
Cancer Research
Toxicology
Oncology
Pharmacology
Phase I Dose Finding Studies of Obatoclax (GX15-070), a Small Molecule Pan-BCL-2 Family Antagonist, in Patients With Advanced Solid Tumors or Lymphoma
Clinical Cancer Research
Cancer Research
Oncology
BH4 Domain Peptides Derived From BCL-2/BCL-Xl as Novel Tools Against Acute Pancreatitis
Cell Death Discovery
Cancer Research
Molecular Neuroscience
Immunology
Cell Biology
Cellular
First‐in‐human Phase I Study of E7090, a Novel Selective FGFR Inhibitor, in Patients With Advanced Solid Tumors
Cancer Science
Cancer Research
Medicine
Oncology
HSpin1, a Transmembrane Protein Interacting With BCL-2/BCL-xL, Induces a Caspase-Independent Autophagic Cell Death
Cell Death and Differentiation
Cell Biology
Molecular Biology
Structure-Based Design of Potent BCL-2/BCL-xL Inhibitors With Strong in Vivo Antitumor Activity
Journal of Medicinal Chemistry
Drug Discovery
Molecular Medicine
A Phase I Study of E7080, a Multitargeted Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Tumours
British Journal of Cancer
Cancer Research
Oncology
Combined Inhibition of Notch Signaling and BCL-2/BCL-xL Results in Synergistic Antimyeloma Effect
Molecular Cancer Therapeutics
Cancer Research
Oncology
Overcoming the Radioresistance of Prostate Cancer Cells With a Novel BCL-2 Inhibitor
Oncogene
Cancer Research
Genetics
Molecular Biology
